VIDEO: Concurrent regrowth of scalp hair, eyebrow, eyelash with baricitinib notable

Dec 11, 2023

Healio Interviews

Healio Interviews

if ("1pRc4aob8" === "oYMIsqoPB") { videojs.getPlayer("V3280b977_e929_4eaa_9308_1ae2791a6f3a_6323656874112").ready(function() { var ccPlayer = this; ccPlayer.on("loadedmetadata", function() { // +++ Get the browser language +++ var browser_language = navigator.language || navigator.userLanguage; // IE

In this Healio video exclusive, Laura Korb Ferris, MD, PhD , discusses the efficacy of baricitinib treatment in concurrent scalp hair, eyebrow and eyelash responses.

Results of the research by Brett King, MD, PhD, and colleagues, which were presented at the American Academy of Dermatology Annual Meeting, demonstrated improvement in patients with severe alopecia areata.

In two phase 3 clinical trials, King and colleagues found continuous improvement of scalp, eyebrow and eyelash hair regrowth in patients treated with 2 mg or 4 mg of baricitinib for 52 weeks. More specifically, of the patients in the severe combined hair loss subgroup taking 4 mg baricitinib, 32.9% to 44.8% achieved successful hair regrowth in at least one location.

"There was a correlation between regrowth of eyebrows or eyelashes and regrowth of scalp hair. This becomes important because, for one, we know that baricitinib has a significant impact on severe alopecia areata," Ferris, professor of dermatology at the University of Pittsburgh Clinical and Translational Science Institute, said.

"Two, we also learned from initial clinical trials that hair regrowth was not limited to the scalp," Ferris continued. "It was also seen in the eyelash and the eyebrows. … We can also see that a good response tends to help all of the areas: the scalp, the eyelash and the eyebrow."

Reference: